Also known as Proamatine and Orvaten
Midodrine (brand names Amatine, ProAmatine, Gutron) is a vasopressor/antihypotensive agent. Midodrine was approved in the United States by the Food and Drug Administration (FDA) in 1996 for the treatment of dysautonomia and orthostatic hypotension. In August 2010, the FDA proposed withdrawing this approval because the manufacturer, Shire plc, has failed to complete required studies after the medicine reached the market.Source: Wikipedia
Estimated Total Cost: $105.96 for an average of 28 days supply
Patients are most commonly prescribed midodrine to treat fainting, kidney failure, orthostatic hypotension, and sinus bradycardia.
Patients taking midodrine most commonly experience side effects like retention of urine, painful urination, and frequent urination.